Cipla shines as its arm gets USFDA`s final nod for Albuterol Sulfate Inhalation Aerosol
Cipla is currently trading at Rs. 1272.40, up by 37.40 points or 3.03% from its previous closing of Rs. 1235.00 on the BSE.
The scrip opened at Rs. 1240.70 and has touched a high and low of Rs. 1295.30 and Rs. 1228.80 respectively. So far 84007 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1672.20 on 23-Oct-2025 and a 52 week low of Rs. 1165.55 on 02-Apr-2026.
Last one week high and low of the scrip stood at Rs. 1295.30 and Rs. 1221.95 respectively. The current market cap of the company is Rs. 102911.51 crore.
The promoters holding in the company stood at 29.21%, while Institutions and Non-Institutions held 54.52% and 16.26% respectively.
Cipla’s wholly owned subsidiary -- Cipla USA Inc (Cipla) has received final approval from the United States Food and Drug Administration (USFDA) for the Abbreviated New Drug Application (ANDA) submitted for Albuterol Sulfate Inhalation Aerosol, 90 mcg per actuation, the first AB rated generic therapeutic equivalent of Ventolin HFA, marketed by GlaxoSmithKline.
Albuterol Sulfate Inhalation Aerosol is indicated for the treatment or prevention of bronchospasm in adult and pediatric patients aged four years and older with reversible obstructive airway disease, as well as for the prevention of exercise-induced bronchospasm in patients aged four years and older.
